Acute myeloid leukemia (AML) is a blood cancer caused by various genetic abnormalities in hematopoietic precursor cells which lead to the proliferation of immature white blood cells. As a result, the bone marrow is no longer able to produce normal blood cells. AML can be treated with chemotherapy; however, even in cases with the same genetic abnormality, disease progression often varies. It has not been clear to date why certain forms are more aggressive than others.
Research teams led by Antoine Peters, a Group Leader at the FMI, and by Jürg Schwaller of the University of Basel, Department of Biomedicine and the University Children’s Hospital Basel (UKBB) have now discovered that the aggressiveness of a certain form of AML largely depends on the type of precursor cell in which the genetic alteration occurs. Schwaller says: “These so-called MLL fusion leukemias affect not only very young patients but also patients over 60 who have already undergone chemotherapy.”
Using a mouse model, the researchers showed that the prognosis for this disease is particularly poor if the genetic alteration occurs in hematopoietic stem cells. This type of AML is highly aggressive and is associated with extensive tissue infiltration and resistance to chemotherapy.
The researchers also found that these hematopoietic stem cells express certain genes which promote cell migration and tissue invasion. In later-stage precursor cells, these genes were no longer expressed. Peters notes: “When we reduced expression of one of these genes in the early hematopoietic stem cells, disease progression was much milder.”
Importantly, the findings in mice are also applicable to humans: in samples collected from patients with an aggressive disease course, precisely the same genes were expressed. Peters concludes: “The prognosis thus depends on the particular hematopoietic stem or precursor cells in which the genetic alteration occurs, and what genes are expressed.”
As Schwaller explains, these genes could also serve as biomarkers: “The expression of genes such as EVI1, ERG or ZEB1 now allows us to classify patients into different groups according to prognosis, and if necessary to adapt treatment. Our findings should also enable us to develop new, more personalized therapies for these patients.”
This project was supported by the Swiss National Science Foundation and by the SystemsX.ch Cell Plasticity program.
Stavropoulou V, Kaspar S, Brault L, Sanders MA, Juge S, Morettini S, Tzankov A, Iacovino M, Lau I-J, Milne TA, Royo H, Kyba M, Valk PJM, Peters AHFM, Schwaller J
MLL-AF9 expression in hematopoietic stem cells drives a highly invasive AML expressing EMT-related genes linked to poor outcome
Cancer Cell (2016), doi: 10.1016/j.ccell.2016.05.011
• Prof. Dr. Antoine Peters, Friedrich Miescher Institute for Biomedical Research (FMI), Tel. +41 61 697 87 61, email: firstname.lastname@example.org
• Prof. Dr. Jürg Schwaller, University of Basel/University Children’s Hospital Basel (UKBB), Department of Biomedicine, Tel. +41 61 265 35 04, email: email@example.com
• Dr. Sandra Ziegler, FMI Communications, Tel. +41 61 696 15 39, email: firstname.lastname@example.org